BRPI0416227A - micropartìculas compreendendo análogos de somatostatina - Google Patents

micropartìculas compreendendo análogos de somatostatina

Info

Publication number
BRPI0416227A
BRPI0416227A BRPI0416227-7A BRPI0416227A BRPI0416227A BR PI0416227 A BRPI0416227 A BR PI0416227A BR PI0416227 A BRPI0416227 A BR PI0416227A BR PI0416227 A BRPI0416227 A BR PI0416227A
Authority
BR
Brazil
Prior art keywords
microparticles
somatostatin analogs
somatostatin
biocompatible
understanding
Prior art date
Application number
BRPI0416227-7A
Other languages
English (en)
Inventor
Markus Ahlheim
Michael Ausborn
Olivier Lambert
Marc Riemen-Schnitter
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34593737&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0416227(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0326602A external-priority patent/GB0326602D0/en
Priority claimed from GB0406241A external-priority patent/GB0406241D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0416227A publication Critical patent/BRPI0416227A/pt
Publication of BRPI0416227B1 publication Critical patent/BRPI0416227B1/pt
Publication of BRPI0416227B8 publication Critical patent/BRPI0416227B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/788—Of specified organic or carbon-based composition

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)

Abstract

"MICROPARTìCULAS COMPREENDENDO ANáLOGOS DE SOMATOSTATINA". A presente invenção refere-se a micropartículas compreendendo um análogo de somatostatina incrustadas em uma matriz polimérica biocompatível e farmacologicamente aceitável para uma liberação de longa ação e composições farmacêuticas compreendendo essas micropartículas.
BRPI0416227A 2003-11-14 2004-11-12 micropartículas compreendendo análogos de somatostatina, seu uso, composição famacêutica e kit BRPI0416227B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0326602.0 2003-11-14
GB0326602A GB0326602D0 (en) 2003-11-14 2003-11-14 Organic compounds
GB0406241.0 2004-03-19
GB0406241A GB0406241D0 (en) 2004-03-19 2004-03-19 Organic compounds
PCT/EP2004/012870 WO2005046645A1 (en) 2003-11-14 2004-11-12 Microparticles comprising somatostatin analogues

Publications (3)

Publication Number Publication Date
BRPI0416227A true BRPI0416227A (pt) 2007-01-02
BRPI0416227B1 BRPI0416227B1 (pt) 2019-06-18
BRPI0416227B8 BRPI0416227B8 (pt) 2021-05-25

Family

ID=34593737

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0416227A BRPI0416227B8 (pt) 2003-11-14 2004-11-12 micropartículas compreendendo análogos de somatostatina, seu uso, composição famacêutica e kit

Country Status (30)

Country Link
US (3) US7759308B2 (pt)
EP (1) EP1686964B9 (pt)
JP (1) JP4682145B2 (pt)
KR (1) KR101233892B1 (pt)
AR (1) AR047310A1 (pt)
AT (1) ATE455537T1 (pt)
AU (1) AU2004289055C1 (pt)
BR (1) BRPI0416227B8 (pt)
CA (1) CA2541944C (pt)
CY (2) CY1110293T1 (pt)
DE (1) DE602004025271D1 (pt)
DK (1) DK1686964T3 (pt)
EC (1) ECSP066565A (pt)
ES (1) ES2339026T3 (pt)
HR (1) HRP20100190T1 (pt)
IL (1) IL175286A (pt)
IS (1) IS8480A (pt)
LU (1) LU92701I2 (pt)
MA (1) MA28155A1 (pt)
MX (1) MXPA06005357A (pt)
MY (1) MY158342A (pt)
NO (2) NO337172B1 (pt)
NZ (1) NZ546788A (pt)
PE (1) PE20050581A1 (pt)
PL (1) PL1686964T3 (pt)
PT (1) PT1686964E (pt)
RU (1) RU2404749C2 (pt)
SI (1) SI1686964T1 (pt)
TW (1) TWI295178B (pt)
WO (1) WO2005046645A1 (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY158342A (en) * 2003-11-14 2016-09-30 Novartis Ag Pharmaceutical composition
KR20130024987A (ko) * 2005-12-22 2013-03-08 노파르티스 아게 옥트레오티드 및 ２종 이상의 폴리락티드-코-글리콜리드 중합체를 포함하는 서방형 제제
KR100816065B1 (ko) * 2006-11-27 2008-03-24 동국제약 주식회사 초기 방출억제 특성이 우수한 서방출성 마이크로캡슐의제조방법 및 이에 의해 제조되는 마이크로캡슐
WO2008143992A2 (en) * 2007-05-18 2008-11-27 Durect Corporation Improved depot formulations
PE20090387A1 (es) * 2007-05-24 2009-04-28 Novartis Ag Formulacion de pasireotida
CN101917969A (zh) * 2008-01-30 2010-12-15 诺瓦提斯公司 包含奥曲肽和三种线形聚丙交酯-共-乙交酯聚合物的缓释制剂
US9629798B2 (en) * 2008-04-03 2017-04-25 Mallinckrodt Pharma Ip Trading D.A.C. Hemostatic microspheres
DK2310042T3 (da) 2008-07-08 2013-03-04 Novartis Ag Anvendelse af pasireotid til behandling af endogen hyperinsulinæmisk hypoglykæmi
US20100151033A1 (en) * 2008-12-15 2010-06-17 Novartis Ag Octreotide depot formulation with constantly high exposure levels
US8822610B2 (en) 2008-12-22 2014-09-02 ATRP Solutions, Inc. Control over controlled radical polymerization processes
US8815971B2 (en) 2008-12-22 2014-08-26 ATRP Solutions, Inc. Control over controlled radical polymerization processes
US9783628B2 (en) 2009-04-23 2017-10-10 ATRP Solutions, Inc. Dual-mechanism thickening agents for hydraulic fracturing fluids
US8173750B2 (en) 2009-04-23 2012-05-08 ATRP Solutions, Inc. Star macromolecules for personal and home care
WO2010123574A1 (en) 2009-04-23 2010-10-28 Atrp Solutions Inc Star macromolecules for personal and home care
US9587064B2 (en) 2010-12-08 2017-03-07 ATRP Solutions, Inc. Salt-tolerant star macromolecules
WO2013131879A1 (en) 2012-03-07 2013-09-12 Novartis Ag New application for pasireotide
CN105189643B (zh) 2012-08-30 2019-01-15 派诺聚合物技术公司 用于水力压裂液的双重机制增稠剂
MX374990B (es) 2013-02-04 2025-03-06 Pilot Polymer Tech Inc Métodos para la elaboración de macromoléculas en forma de estrella tolerantes a las sales que comprende una pluralidad de brazos poliméricos.
JP2016512523A (ja) 2013-03-11 2016-04-28 デュレクト コーポレーション 高粘性液体キャリアを含む注射用制御放出組成物
TW201605488A (zh) * 2013-10-15 2016-02-16 大塚製藥股份有限公司 用以預防及／或治療多囊腎病之藥物
CN107075015B (zh) 2014-07-03 2019-08-23 派诺聚合物技术公司 表面活性剂-相容性星形大分子

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU221294B1 (en) * 1989-07-07 2002-09-28 Novartis Ag Process for producing retarde compositions containing the active ingredient in a polymeric carrier
PH30995A (en) 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
MY147327A (en) 1995-06-29 2012-11-30 Novartis Ag Somatostatin peptides
AU5678398A (en) * 1997-01-29 1998-08-18 Takeda Chemical Industries Ltd. Sustained-release microspheres, their production and use
EP1098660B1 (en) * 1998-07-23 2002-10-16 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Encapsulation of water soluble peptides
WO2000004916A1 (en) * 1998-07-23 2000-02-03 Societe De Conseils De Recherches Et D'applications Scientifiques Sas Encapsulation of water soluble peptides
EP1240896A3 (en) * 1998-07-23 2003-03-26 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Encapsulation of water soluble peptides
DE60027334T2 (de) 1999-08-18 2007-03-29 Société de Conseils de Recherches et d'Applications Scientifiques S.A.S. Zusammensetzung mit verzögerter Abgabe in der ein Peptid mit einem Polymer komplexiert ist
GB0018891D0 (en) * 2000-08-01 2000-09-20 Novartis Ag Organic compounds
AU2003221497A1 (en) * 2002-03-13 2003-09-22 Novartis Ag Pharmaceutical microparticles
MY158342A (en) * 2003-11-14 2016-09-30 Novartis Ag Pharmaceutical composition

Also Published As

Publication number Publication date
DK1686964T3 (da) 2010-05-17
IL175286A0 (en) 2006-09-05
EP1686964B9 (en) 2010-08-04
CY2015011I2 (el) 2016-04-13
JP2007511482A (ja) 2007-05-10
CY1110293T1 (el) 2015-01-14
AR047310A1 (es) 2006-01-18
PE20050581A1 (es) 2005-09-09
AU2004289055B2 (en) 2008-10-30
NO2016003I1 (no) 2016-02-02
KR101233892B1 (ko) 2013-02-18
DE602004025271D1 (de) 2010-03-11
MA28155A1 (fr) 2006-09-01
KR20060115873A (ko) 2006-11-10
IL175286A (en) 2012-05-31
TWI295178B (en) 2008-04-01
NO2016003I2 (no) 2016-02-02
MXPA06005357A (es) 2006-07-10
IS8480A (is) 2006-05-23
NO20062777L (no) 2006-08-14
NO337172B1 (no) 2016-02-01
US20120214749A1 (en) 2012-08-23
CY2015011I1 (el) 2016-04-13
AU2004289055A1 (en) 2005-05-26
HRP20100190T1 (hr) 2010-06-30
US20100272809A1 (en) 2010-10-28
SI1686964T1 (sl) 2010-05-31
EP1686964A1 (en) 2006-08-09
ECSP066565A (es) 2006-10-17
BRPI0416227B8 (pt) 2021-05-25
TW200529883A (en) 2005-09-16
WO2005046645A1 (en) 2005-05-26
CA2541944A1 (en) 2005-05-26
PL1686964T3 (pl) 2010-06-30
AU2004289055C1 (en) 2009-05-21
EP1686964B1 (en) 2010-01-20
ES2339026T3 (es) 2010-05-14
LU92701I2 (fr) 2015-11-02
US20070212418A1 (en) 2007-09-13
NZ546788A (en) 2009-12-24
HK1093682A1 (en) 2007-03-09
US7759308B2 (en) 2010-07-20
MY158342A (en) 2016-09-30
BRPI0416227B1 (pt) 2019-06-18
RU2404749C2 (ru) 2010-11-27
ATE455537T1 (de) 2010-02-15
RU2006120484A (ru) 2007-12-27
US8188037B2 (en) 2012-05-29
CA2541944C (en) 2014-02-25
PT1686964E (pt) 2010-02-04
JP4682145B2 (ja) 2011-05-11

Similar Documents

Publication Publication Date Title
BRPI0416227A (pt) micropartìculas compreendendo análogos de somatostatina
HRP20090381T1 (en) Compositions comprising drospirenone molecularly dispersed
IL199052A0 (en) Hla-a*1101-restricted wt1 peptide and pharmaceutical composition comprising the same
SI1988163T1 (sl) HLA-A*3303-omejen WT1 peptid in farmacevtski sestavek, ki ga vsebuje
BRPI0414565A (pt) composições farmacêuticas e métodos que compreendem combinações de derivados de 2-alquilideno-19-nor-vitamina d e um bisfosfonato
DK1467724T3 (da) Farmaceutisk sammensætning med agomelatin til dispergering i mundhulen
FR2858624B1 (fr) Composition electrostatique a base de matrice polyamide
TWI319318B (en) Modified release pharmaceutical formulation
AU2003260803A8 (en) Sustained release pharmaceutical composition
GT200800107A (es) Formulaciones orales que comprenden tigeciclina
BR0316236A (pt) Dispositivo polimérico de dissolução controlada para cavidade oral
BRPI0212298B8 (pt) composição farmacêutica compreendendo gabapentina ou um análogo da mesma e (alfa)-aminoamida e seu uso analgésico
SI1800669T1 (sl) Orodisperzibilni farmacevtski sestavek za peroralno oromukozalno ali sublingvalno dajanje agomelatina
PL376015A1 (en) Pharmaceutical composition comprising octreotide microparticles
BRPI0413676A (pt) composto, e, composição farmacêutica
NO20062111L (no) 2-(3,4-dimetylfenyl)-4-{[2-hydroksy-3'(1H-tetrazol-5-yl)]-hydrazon}-5-metyl-2,4-dihydropyrozol-3-on kolin.
ATE327759T1 (de) Pharmazeutische zusammensetzung mit verlungerter freisetzung
BRPI0408848A (pt) formulações orais de cladribine
EP1478353A4 (en) PHARMACEUTICAL COMPOSITION WITH DELAYED RELEASE
PL370162A1 (en) Orodispersible pharmaceutical composition comprising perindopril
BRPI0516922A (pt) composto de ribavirina, método para fazer um composto de ribavirina, método para usar um composto de ribavirina e composição farmacêutica
SI1648934T1 (sl) Farmacevtski sestavek, ki obsega ciklične somatostatinske analoge
TNSN06136A1 (en) Microparticles comprising somatostatin analogues
TNSN05310A1 (en) Pharmaceutical composition comprising cyclic somatostatin analogues
MX2008006476A (es) Composiciones de lipopeptidos.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: AS CLASSIFICACOES ANTERIORES ERAM: A61K 9/16 , A61K 38/31

Ipc: A61K 38/31 (2006.01), A61K 9/16 (2006.01), A61P 5/

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 18/06/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 18/06/2019, OBSERVADAS AS CONDICOES LEGAIS

B25A Requested transfer of rights approved

Owner name: RECORDATI AG (CH)

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 12/11/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 21A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2854 DE 16-09-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.